TEICOPLANIN-AFT (AFT Pharmaceuticals Pty Ltd)
Product name
TEICOPLANIN-AFT
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
111 (255 working days)
Active ingredients
Teicoplanin
Registration type
New generic medicine
Indication
Teicoplanin-AFT is indicated for the treatment of the following serious infections due to staphylococci or streptococci, which cannot be treated satisfactorily with less toxic agents, including β-lactam antibiotics:
Bone - osteomyelitis
Joints - septic arthritis
Blood - non-cardiac bacteraemia, septicaemia